RESUMEN
Somatostatin receptors (SS-Rs) have been found on a variety of neuroendocrine tumors like carcinoids, paragangliomas, as well as on brain and breast tumors. SS-Rs are also present on most pancreatic endocrine tumors, while previous in vitro studies indicate the absence of these receptors on pancreatic duct cancers. Somatostatin receptor scintigraphy with a radionuclide labeled somatostatin analogue, [111In-DTPA0]-octreotide, is a sensitive and specific technique to visualize in vivo the presence of SS-Rs on various tumors. The purpose of this article is to review the somatostatin receptor imaging of pancreatic endocrine tumors and to illustrate the impact of SS-R expression for therapeutic strategies.
Asunto(s)
Apudoma/radioterapia , Neoplasias Pancreáticas/radioterapia , Receptores de Somatostatina/análisis , Apudoma/química , Humanos , Radioisótopos de Indio/uso terapéutico , Octreótido/metabolismo , Octreótido/uso terapéutico , Neoplasias Pancreáticas/química , Ácido PentéticoAsunto(s)
Radioisótopos de Yodo/uso terapéutico , Yodobencenos/uso terapéutico , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/radioterapia , 3-Yodobencilguanidina , Apudoma/diagnóstico , Apudoma/radioterapia , Humanos , Neuroblastoma/diagnóstico , Neuroblastoma/radioterapia , Feocromocitoma/diagnóstico , Feocromocitoma/radioterapiaRESUMEN
A case of Merkel cell tumour of the face and its dramatic response to a course of radical radiotherapy is presented below. The patient has been free of recurrence for 18 months and has suffered minimal side-effects from the treatment. This suggests that radical radiotherapy, as opposed to the standard wide excision, may be the preferred first-line treatment for at least some of these rare, but highly malignant tumours.
Asunto(s)
Apudoma/radioterapia , Neoplasias Faciales/radioterapia , Anciano , Párpados , Humanos , MasculinoAsunto(s)
Apudoma/terapia , Neoplasias Pancreáticas/terapia , Apudoma/tratamiento farmacológico , Apudoma/radioterapia , Apudoma/cirugía , Terapia Combinada , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/radioterapia , Neoplasias Pancreáticas/cirugíaRESUMEN
This paper attempts to review current opinions on medullary thyroid carcinoma. Histologically described for the first time in 1951 belongs to the endocrine-secreting group of tumours (APUD). It can be sporadic as well as hereditary. The histological classification nowadays is increasingly performed immunohistologically via calcitonin. Clinically the tumour ranges from the very small, but hormonally highly active form, to the aggressive, mostly undifferentiated form. According to this the therapy must be radical. Our study group recommends thyroidectomy and functional neck dissection, followed by radio-chemotherapy. A close interdisciplinary follow up of the patients is necessary. Our surgical department treated 1048 thyroid malignancies between 1949 and 1982. 26 patients (2.4%) were diagnosed to have medullary thyroid carcinoma. Follow up time was between 1 month and 17 years. The recurrence--free interval was 4.5 years. The 5 and 10 year survival rate was 52% and 26%, respectively.
